Prospective LocoMMotion study of real-life standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma

Treatment of relapsed or refractory multiple myeloma (RRMM) is challenging as patients exhaust all available therapies and the disease becomes refractory to standard drug classes. The prospective LocoMMotion study evaluated real-world clinical practice (RWCP) in triple-class exposed (TCE) patients with RRMM at 75 centers in Europe. Final analysis of the study (median follow-up 26.4 months; range 0.1-35.0) has now been published. The study included 248 patients who at inclusion had received median 4 prior lines of treatmen (LOT; range 2-13). 91 unique regimens were used in index LOT. Overall response rate was 31.9% (95% CI 26.1-38.0). Median progression-free survival and overall survival were 4.6 months (95%CI 3.9-5.6) and 13.8 months (10.8-17.0), respectively. 152 patients had subsequent LOTs with 134 unique regimens. Median PFS2 (from inclusion through first subsequent LOT) was 10.8 months (95% CI 8.4-13.0). 158 patients died on study; 67.7% due to progressive disease. The authors conclude that the high number of RWCP treatment regimes used and poor clinical outcomes confirm a lack of standardized treatment for TCE patients with RRMM, highlighting the need for new treatments with novel mechanisms.